Health1 min read

Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria

By · Via STAT Health · Published by Everything Blog

In short

In a Mali trial, the monoclonal antibody L9LS proved 78% effective over six months but reduced immune responses from the subsequent R21 vaccine by 20% to 30%. Researchers believe L9LS intercepted the vaccine because both interventions target the malaria parasite's circumsporozoite protein. Although the real-world consequence of this reduced immune response remains uncertain, scientists are shifting their immediate focus away from infants. Pivotal trials planned for 2028 will now prioritize alternative vulnerable demographics, including pregnant people and children recovering from malaria hospitalizations.

Key points

  • Direct interference between shared target mechanisms can significantly weaken the immune…: Direct interference between shared target mechanisms can significantly weaken the immune response when antibodies and vaccines are combined.
  • Researchers are postponing pediatric combination strategies to focus pivotal 2028 approva…: Researchers are postponing pediatric combination strategies to focus pivotal 2028 approval trials on other high-risk demographics.
  • A single dose of L9LS can provide several months of defense for vulnerable populations de…: A single dose of L9LS can provide several months of defense for vulnerable populations despite higher manufacturing costs.

Sources checked by our analysis pipeline: 1

When it comes to preventing malaria, researchers and public health officials have been hopeful about the potential of a monoclonal antibody, one injection of which could provide recipients with several months of protection against the parasite. Such a tool, experts have thought, could give babies a layer of defense even before they start receiving doses of the malaria vaccines that have rolled out in recent years.

New research detailed Thursday has cast doubt on that strategy.

Scientists tested the monoclonal, known as L9LS, in infants in Mali, finding that it was 78% effective versus a placebo in providing protection against the malaria parasite over the six-month transmission season, similar to what has been seen in studies of the antibody in older kids and adults.

However, they also reported that it interfered with the immune response the malaria vaccine R21 elicits, resulting in a 20% to 30% drop in antibody levels generated by the immunization, according to an abstract presented at the annual meeting of the American Society of Tropical Medicine and Hygiene.

While it’s not clear what the diminished immune…

Health